Free Trial

Zevra Therapeutics (ZVRA) Competitors

Zevra Therapeutics logo
$11.61 +0.06 (+0.52%)
As of 01:24 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

ZVRA vs. VCEL, AGIO, CGON, KNSA, BEAM, IDYA, IRON, BLTE, CNTA, and HRMY

Should you be buying Zevra Therapeutics stock or one of its competitors? The main competitors of Zevra Therapeutics include Vericel (VCEL), Agios Pharmaceuticals (AGIO), CG Oncology (CGON), Kiniksa Pharmaceuticals International (KNSA), Beam Therapeutics (BEAM), IDEAYA Biosciences (IDYA), Disc Medicine (IRON), Belite Bio (BLTE), Centessa Pharmaceuticals (CNTA), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry.

Zevra Therapeutics vs. Its Competitors

Zevra Therapeutics (NASDAQ:ZVRA) and Vericel (NASDAQ:VCEL) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, media sentiment, institutional ownership and dividends.

In the previous week, Zevra Therapeutics had 8 more articles in the media than Vericel. MarketBeat recorded 10 mentions for Zevra Therapeutics and 2 mentions for Vericel. Vericel's average media sentiment score of 0.92 beat Zevra Therapeutics' score of 0.79 indicating that Vericel is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zevra Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Vericel
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Vericel has higher revenue and earnings than Zevra Therapeutics. Zevra Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zevra Therapeutics$23.61M26.89-$105.51M-$1.90-6.11
Vericel$237.22M8.73$10.36M$0.031,371.83

Zevra Therapeutics presently has a consensus price target of $23.14, indicating a potential upside of 99.34%. Vericel has a consensus price target of $61.14, indicating a potential upside of 48.57%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Zevra Therapeutics is more favorable than Vericel.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zevra Therapeutics
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
3.11
Vericel
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00

Zevra Therapeutics has a beta of 1.97, suggesting that its share price is 97% more volatile than the S&P 500. Comparatively, Vericel has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500.

35.0% of Zevra Therapeutics shares are owned by institutional investors. 2.4% of Zevra Therapeutics shares are owned by insiders. Comparatively, 7.2% of Vericel shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Vericel has a net margin of 1.25% compared to Zevra Therapeutics' net margin of -226.78%. Vericel's return on equity of 1.09% beat Zevra Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Zevra Therapeutics-226.78% -201.05% -53.55%
Vericel 1.25%1.09%0.73%

Summary

Vericel beats Zevra Therapeutics on 9 of the 17 factors compared between the two stocks.

Get Zevra Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZVRA vs. The Competition

MetricZevra TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$634.84M$2.70B$5.54B$9.00B
Dividend YieldN/A1.79%5.25%4.04%
P/E Ratio-6.119.1827.1820.18
Price / Sales26.89752.24431.49125.05
Price / CashN/A159.8036.8257.86
Price / Book15.694.618.085.59
Net Income-$105.51M$31.26M$3.17B$248.60M
7 Day Performance23.38%6.81%4.13%5.18%
1 Month Performance26.33%4.04%3.80%7.11%
1 Year Performance112.05%3.46%34.35%21.73%

Zevra Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZVRA
Zevra Therapeutics
2.7609 of 5 stars
$11.61
+0.5%
$23.14
+99.3%
+157.2%$634.84M$23.61M-6.1120
VCEL
Vericel
2.9585 of 5 stars
$41.79
+0.8%
$61.14
+46.3%
-14.4%$2.10B$237.22M1,393.30300
AGIO
Agios Pharmaceuticals
4.0718 of 5 stars
$36.06
+2.0%
$58.60
+62.5%
-11.9%$2.09B$36.50M3.21390
CGON
CG Oncology
2.3516 of 5 stars
$26.90
+0.8%
$58.67
+118.1%
-19.0%$2.05B$1.14M-17.8161
KNSA
Kiniksa Pharmaceuticals International
3.3994 of 5 stars
$27.86
+1.5%
$38.80
+39.3%
+37.0%$2.03B$423.24M-111.42220Analyst Upgrade
BEAM
Beam Therapeutics
2.649 of 5 stars
$20.02
+0.7%
$48.75
+143.5%
-14.9%$2.01B$63.52M0.00510Gap Up
IDYA
IDEAYA Biosciences
3.2418 of 5 stars
$22.09
+0.8%
$53.42
+141.8%
-45.7%$1.94B$7M-6.1580Analyst Forecast
IRON
Disc Medicine
3.1595 of 5 stars
$54.75
+3.0%
$96.70
+76.6%
+11.5%$1.90BN/A0.0030Insider Trade
BLTE
Belite Bio
2.4234 of 5 stars
$59.74
+5.2%
$96.67
+61.8%
+23.7%$1.89BN/A0.0010Analyst Revision
CNTA
Centessa Pharmaceuticals
3.1671 of 5 stars
$14.34
+4.3%
$27.89
+94.6%
+50.3%$1.88B$6.85M0.00200
HRMY
Harmony Biosciences
4.827 of 5 stars
$32.09
-0.1%
$53.63
+67.1%
+0.6%$1.85B$714.73M12.27200Positive News

Related Companies and Tools


This page (NASDAQ:ZVRA) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners